Loading...

Neutra Corp.

NTRRPNK
Healthcare
Biotechnology
$0.00
$0.00(100.00%)

Neutra Corp. (NTRR) Financial Performance & Income Statement Overview

Explore the financials of Neutra Corp. (NTRR), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
-41.86%
41.86%
Operating Income Growth
22.91%
22.91%
Net Income Growth
58.42%
58.42%
Operating Cash Flow Growth
93.25%
93.25%
Operating Margin
-154.91%
154.91%
Gross Margin
94.56%
94.56%
Net Profit Margin
-160.19%
160.19%
ROE
10.72%
10.72%
ROIC
10.09%
10.09%

Neutra Corp. (NTRR) Income Statement & Financial Overview

Analyze Neutra Corp.’s NTRR earnings with segmented quarterly and yearly financial statement figures.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$32375.00$28056.00$1311.00$4325.00
Cost of Revenue$1420.00$25219.00$722.00$2643.00
Gross Profit$30955.00$2837.00$589.00$1682.00
Gross Profit Ratio$0.96$0.10$0.45$0.39
R&D Expenses$0.00$0.00$0.00$0.00
SG&A Expenses$45319.00$36618.00$44266.00$60412.00
Operating Expenses$46440.00$36618.00$53317.00$73451.00
Total Costs & Expenses$47860.00$61837.00$54039.00$76094.00
Interest Income$0.00$0.00$0.00$29.00
Interest Expense$867.00$854.00$2258.00$29.00
Depreciation & Amortization$1121.00$6423.00$9051.00$13039.00
EBITDA-$14364.00-$27358.00-$43677.00-$58730.00
EBITDA Ratio-$0.44-$0.98-$33.32-$13.58
Operating Income-$15485.00-$33780.00-$52728.00-$71769.00
Operating Income Ratio-$0.48-$1.20-$40.22-$16.59
Other Income/Expenses (Net)-$867.00-$854.00-$2258.00-$29.00
Income Before Tax-$16352.00-$34635.00-$54986.00-$71798.00
Income Before Tax Ratio-$0.51-$1.23-$41.94-$16.60
Income Tax Expense$0.00$1.00$0.00$49.00
Net Income-$16352.00-$34636.00-$54986.00-$71847.00
Net Income Ratio-$0.51-$1.23-$41.94-$16.61
EPS$0.00$0.00$0.00$0.00
Diluted EPS$0.00$0.00$0.00$0.00
Weighted Avg Shares Outstanding$2.92B$2.92B$2.92B$2.92B
Weighted Avg Shares Outstanding (Diluted)$2.92B$2.92B$2.92B$2.92B

Financial performance has remained strong, with revenue growing from $4325.00 in Q2 2024 to $32375.00 in Q1 2025. Gross profit continued to perform well, with margins at 96% in the latest quarter. Operating income reached -$15485.00 in Q1 2025, holding a steady -48% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$14364.00. Net income rose to -$16352.00, keeping EPS at $0.00. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;